AXS-14, esreboxetine, is a novel, oral, investigational medicine. It is a highly selective and potent norepinephrine reuptake inhibitor.
Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine.
AXS-14 has met the primary endpoints and demonstrated positive and statistically significant results in a Phase 3 and in a Phase 2 trial for the treatment of fibromyalgia.
- AXS-14 was associated with significant improvements in pain, Fibromyalgia Impact Questionnaire (FIQ), Patient Global Impression of Change (PGIC), and fatigue scores compared with placebo.
AXS-14 is an investigational drug not approved by the FDA.
clinical and regulatory
AXS-14 is currently being developed for the treatment of fibromyalgia.